Major indices post gains with the S&P 500 touching a new high as investors anticipate potential monetary easing from the Federal Reserve.
With a potential market of 128 million in the U.S., analysts see blockbuster potential for the new presbyopia treatment.
Positive Phase 1 results for the company's epilepsy drug candidate are coupled with a significant financing deal that could dilute shares.
Tecentriq in combination with Zepzelca approved as a first-line maintenance treatment for extensive-stage small cell lung cancer, a significant advancement for a hard-to-treat cancer.
The approval covers a first-line maintenance treatment for an aggressive form of small cell lung cancer, a historically difficult-to-treat disease.
The ongoing government shutdown has postponed the release of key economic data, leaving the Federal Reserve and investors in the dark.
The regulator's green light for Rhapsido, a first-in-class oral treatment for chronic hives, positions the company to challenge injectable rivals.
Gene therapy candidate TSHA-102 for Rett syndrome receives key designation, paving the way for an accelerated regulatory pathway.